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Abstract
Background: HemoHIM, which is an herbal preparation of three edible herbs (Angelicam gigas Nakai, Cnidium
offinale Makino, and Peaonia japonica Miyabe), is known to have various biological and immunological activities,
but the modulatory effects of this preparation on dendritic cells (DCs)-mediated immune responses have not
been examined previously. DCs are a unique group of white blood cells that initiate primary immune responses
by capturing, processing, and presenting antigens to T cells.
Results: In the present study, we investigated the effect of HemoHIM on the functional and phenotypic maturation
of murine bone marrow-derived dendritic cells (BMDCs) both in vitro and in vivo. The expression of co-stimulatory
molecules (CD40, CD80, CD86, MHC I, and MHC II) and the production of cytokines (IL-1β, IL-6, IL-12p70, and TNF-α) were
increased by HemoHIM in BMDCs. Furthermore, the antigen-uptake ability of BMDCs was decreased by HemoHIM, and
the antigen-presenting ability of HemoHIM-treated mature BMDCs increased TLR4-dependent CD4+ and CD8+ T cell
responses.
Conclusions: Our findings demonstrated that HemoHIM induces TLR4-mediated BMDCs functional and phenotypic
maturation through in vivo and in vitro. And our study showed the antigen-presenting ability that HemoHIM-treated
mature BMDCs increase CD4+ and CD8+ T cell responses by in vitro. These results suggest that HemoHIM has the
potential to mediate DC immune responses.
Keywords: Herbal Composition (HemoHIM), Bone Marrow-Derived Dendritic Cells, Toll-Like Receptor 4 (TLR4), CD4+ T
cells, CD8+ T cells
Background
Dendritic cells (DCs) are the immune cells that are re-
sponsible for the presentation of antigens to T cells. The
main functions of DCs are to capture and present anti-
gens on their surfaces and thus activate other immune
cells. DCs are the most potent antigen presenting cells
(APCs) [1], originate from the bone marrow, and play a
pivotal role in the induction of adaptive immunity as ini-
tiators of T cell responses against pathogens and tumors
[2–5]. DCs are found in the peripheral blood of tissues
as immature DCs and are classified as immature or ma-
ture DCs. Immature DCs activate T cells weakly but effi-
ciently capture antigens associated with pathogens,
bacteria, tumors, and inflammatory cytokines and then
begin to mature and migrate to lymph nodes [3, 5–7].
Mature DCs have lower antigen uptake abilities than im-
mature DCs but express higher levels of co-stimulatory
molecules and major histocompatibility complex class
(MHC) I and II on their surfaces [1, 8]. These cells play
key roles in the antigen-specific T cell responses that are
required to initiate adaptive immune responses [2, 3, 9].
In particular, mature DCs induce the activation of
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helper-T cells, cytotoxic-T cells and cell-mediated im-
mune responses and enhance the anti-tumor effects of
cytotoxic-T cells [10]. Recent research reveals the devel-
opment of DC-based anti-tumor immunotherapy, which
is driven by the strong interaction between DCs and T
cells, whereby DCs present tumor antigens via MHC I
and MHC II and thus activate tumor-specific- CD8+ and
CD4+ T cells [10–12]. Like APCs and other immune
cells, DCs express specific repertoires of Toll-like recep-
tors (TLRs), which are capable of recognizing microbial
components [7, 10, 13], binding to corresponding
ligands, and triggering signaling pathways that induce
DC activation [7, 10, 13]. TLRs have been reported to be
the key receptors responsible for recognizing specific
components of antigens [14]. Of the various TLRs, TLR-
2 and TLR-4 are particularly important markers of DC
activation [15–17], and participate in innate defense
against bacterial infections [15, 18–20]. Furthermore,
these receptors have been implicated in the activation of
DCs by exogenous and endogenous adjuvants [12], and
TLR-4 usually induces Th1 activation. [10].
HemoHIM is a well-known herbal mixture that con-
sists of consisting of Angelica Radix, Cnidii Rhizoma,
and Paeonia Radix [21–31] and has been reported to
inhibit various activities of human mast cells [23, 24], to
increase the secretion of IFN-γ and IL-2, to decrease the
secretion of IL-4 by the spleen and lymphocytes [24, 25],
to improve immune function [21, 24], to exert anti-
inflammatory effects on carrageenan-induced edema
[21], to ameliorate oxidative stress, such as stress in-
duced by irradiation [26], and to affect the activation of
immune cells [27]. In addition, HemoHIM has been re-
ported to act as an immune-modulatory agent [28–30],
to have anti-tumor effects [31], and to rescue white
blood cells and lymphocytes exposed to ionizing radi-
ation (IR) [21].
In this study, we investigated whether HemoHIM en-
hances the functions of DCs for potential applications in
DC-based anti-tumor therapy. In particular, we investi-
gated the HemoHIM-induced TLR4-mediated functional
and phenotypic maturation of bone marrow-derived
dendritic cells (BMDCs) and the efficiency of antigen-
presentation by these cells to CD4+ T cells and CD8+ T
cells.
Methods
Animals and experimental treatments in vivo
Female 8- to 12-week-old C57BL/6 mice, weighing 20-
22 g, were purchased from Orientbio (Orientbio Inc.,
Iksan, Korea). Female 8- to 12-week-old BALB/c mice,
weighing 20-22 g, were purchased from DAE-HAN Bio-
link (Eumseong, Korea). Male 8- to 12-week-old C57BL/
6 wild-type, TLR2-deficient, and TLR4-deficient mice
were obtained from Dr. Park (College of Medicine,
Konyang University, Daejeon, Korea). The animals were
housed in a controlled environment [22 ± 2 °C and 50 ±
5 % (relative humidity)] in polycarbonate cages, and fed
a standard animal diet with water. For in vivo experi-
ments, mice were randomly divided in to 2 groups of 6
animals. Control group was orally administered with
sterilized distilled water (D.W) alone (200 μl/mice) once
a day for 4 weeks. And Treatment group was orally ad-
ministered with HemoHIM (100 mg/kg) in D.W (200 μl/
mice) once a day for 4 weeks [21, 32]. All mice were
treated in strict accordance with the guidelines issued
for the care and use of laboratory animals by the
Sunchon National University Institutional Animal Care
and Use Committee (SCNU IACUC). All procedures
were approved by the SCNU IACUC (Permit Number:
2013-1).
Reagents and antibodies
Recombinant mouse granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin (rmIL)-4
were purchased from R&D Systems (Minneapolis, MN,
USA), Dextran-FITC (40,000 Da), propidium iodide (PI),
ovalbumin (OVA), and mitomycin C (MMC) were pur-
chased from Sigma-Aldrich (Steinheim, Germany), and
carboxyfluorescein succinimidyl ester (CFSE), lipopoly-
saccharide (LPS), and Pam3CSK4 (Pam3) were pur-
chased from Invitrogen (Carlsbad, CA, USA). The
following FITC- or PE- conjugated monoclonal anti-
bodies (Abs) and non-labeled Abs were purchased from
BD Biosciences (San Jose, CA, USA) : FITC-annexin V,
CD16/32 (2.4G2), CD11c (HL3), CD40 (HM40–3),
CD80 (16–10A1), CD86 (GL1), H-2Kb (AF6-88.5), I-
A[b] (AF6–120.1), and CCR7 (4B12). Cytokine ELISA
primary and secondary -antibodies specific for murine
IL-1β, IL-6, IL-12p70, IFN-γ, IL-4 and TNF-α were pur-
chased from BD Biosciences (San Jose, CA, USA), and
the OT-1 peptide (OVA257-264) was purchased from Invi-
vogen (San Diego, CA, USA). CD4+ T cell isolation kit
II, CD11c Isolation Kit II and Separation Columns were
purchased from MACS Miltenyi Biotec (Auburn, USA).
5-Bromo-2′-Deoxy-Uridine Labeling and Detection Kit
III were purchased from Roche (Salt Lake City, UT,
USA).
Preparation of HemoHIM
Equal amounts of the three edible medical herbs [i.e.,
Angelica Radix (roots of Angelica gigas Nakai), Cnidii
Rhizoma (roots of Cnidium offinale Makino), and Paeo-
nia Radix (roots of Paeonia japonica Miyabe)] were
mixed at 1:1:1 ratio. To obtain the total extract (HIM-I),
this mixture was decocted for 4 h in boiling water. And
then, the total extract (HIM-I) was divided into two
parts. The ethanol-insoluble polysaccharide fraction was
obtained by from one part of total extract (HIM-I) by
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precipitation in 80 % (vol/vol) ethanol and then added to
the other part of total extract (HIM-I), freeze-dried, and
stored at −20 °C (HemoHIM). HemoHIM was composed
of carbohydrates (60.4 %), protein (6.0 %), and other
components (33.6 %) and other including polyphenols
(33.6 %), (data not shown). The immune modulating
components in HemoHIM were the ethanol-insoluble
fraction, the polysaccharide content was 40.9 % ±3.8
(data not shown) and other carbohydrate components in
HemoHIM were acidic-polysaccharide ethanol soluble
fraction, the polysaccharide content of which was 19.5 %
(data not shown). In addition, the functional component
analysis in the ethanol-soluble fraction of HemoHIM
was performed via high-performance liquid chromatog-
raphy (HPLC) using phytochemicals, as follows: gallic
acid [0.2 % (±0.06)], chlorogenic acid [0.33 % (±0.05)],
paeoniflorin [1.32 % (±0.15)], nodakenin [0.58 %
(±0.04)], and benzoic acid [0.17 % (±0.05)]. In particular,
these herbs are suggested as raw materials in the Korean
Food Code. Finally, HemoHIM has been proven to be
safe for long-term administration [21, 24–26, 29–34].
Generation and activation of bone marrow-derived DCs
BMDCs were obtained from the femurs and tibias of
C57BL/6 mice, and red cells were treated with lysis buf-
fer solution (4.15 g of ammonium chloride per 500 mL
of 0.01 M Tris–HCl buffer). The cells were washed and
cultured in six-well tissue culture plates at 1 × 106 cells/
mL in complete RPMI culture medium supplemented
with 10 % fetal bovine serum (FBS), 2-mecaptoethanol
(50 μM/mL), IL-4 (1,000 U/mL), and GM-CSF (1,000 U/
mL). The culture medium was changed on culture days
2 and 4. New medium and cytokines (i.e., GM-CSF and
IL-4) were added after flushing out non-adherent cells.
On day 6, loosely adherent clustered cells were defined
as immature BMDCs, treated with LPS and HemoHIM
for 24 h and then harvested.
Isolation and activation of spleen-DCs
Mice were orally administered daily for 4 weeks. After
4 weeks, spleen-DCs (s-DCs) from splenocytes suspen-
sions of C57BL/6 mice were isolated using the CD11/c+
isolation kit II and Separation Columns according to the
manufacturer’s instruction. Purity was greater than 94 %.
S-DCs and treated with lipopolysaccharide (LPS, 100 ng/
ml). After 24 h incubation, we analyzed co-stimulatory
of s-DCs using the flow cytometory, and measured cyto-
kine production with ELISA assay [35–43].
Cytotoxicity assay
Apoptosis induction by HemoHIM was quantified via
flow cytometry using Annexin V-FITC and a propidium
iodide (PI) solution, according to the manufacturer’s in-
structions. Briefly, BMDCs (1 × 106/well) were seeded
onto 24-well plates and exposed to HemoHIM or LPS
for 24 h. Apoptosis was quantified by staining with
Annexin V-FITC/PI. Finally, the samples were analyzed
by flow cytometry, and apoptosis percentages were cal-
culated by counting Annexin V-positive cells.
Flow cytometry
After incubation for 24 h, DCs were harvested, washed with
fluorescence-activated cell sorting (FACS) solution buffer,
and blocked with anti-mouse CD16/32, which blocks FcγII
and FcγIII receptors on DCs, for 30 min on ice. After
blocking, the cells were stained with fluorescence-labeled
antibodies (i.e., anti-mouse CD11c-FITC, CD40-PE, CD80-
PE, CD86-PE, MHC I-PE, or MHC II-PE) for 30 min on
ice, washed with FACS solution buffer, and analyzed via
flow cytometry. Data analysis was performed using the BD
FACS Diva software.
Antigen uptake assay
To assess the antigen uptake activity of BMDCs, on cul-
ture day 6, the BMDCs were treated with HemoHIM
(100 μg/ml) and LPS (1 μg/ml) or left untreated for
24 h. Then, 2 × 105 of the obtained mature-BMDCs were
incubated at 37 °C for 2 h with 1 mg/mL FITC-dextran,
washed with FACS solution buffer, and analyzed via flow
cytometry.
OVA-specific Th1 cell preparation
The mice were immunized intraperitoneal injection (i.p.)
with incomplete Freund’s adjuvant (IFA) or complete
Freund’s adjuvant (CFA) (Pierce) and immunized with
OVA on day 0 (OVA-IFA) and on day 7 (OVA-CFA).
Spleens were harvested from OVA-immunized mice on
day 14. CD4+ T cells were isolated from the spleens
using a CD4+ T cell Isolation Kit II and then activated
with OVA (100 μg/ml) and syngeneic APCs. OVA-
specific CD4+ T cells were selected by limiting dilution,
and OVA-specific T (CD4+, IFN-γ+) cells were counted
using a FACScanto II [10, 44, 45].
Proliferation assay of OVA-specific Th1 cells
To investigate the antigen-presenting ability of OVA or
OVA-pulsed HemoHIM BMDCs, 3 × 104 cells were in-
cubated with 5 × 104 OVA-specific Th1 cells for 24 h or
48 h in 200 μl of culture medium in 96-well cell culture
plates. Also, to investigate the antigen-presenting ability
of OVA-pulsed s-DCs of group with oral administered
HemoHIM, 3 × 104 s-DCs of orally administered group
(D.W or HemoHIM) were incubated with 5 × 104 OVA-
specific Th1 cells for 24 h or 48 h in 200 μl of culture
medium in 96-well cell culture plates. Proliferation was
evaluated using a 5-bromo-2′-deoxy-uridine Labeling
and Detection Kit III. Cytokine levels were determined
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via ELISA. The results are expressed as the mean of ex-
periments performed in triplicate.
Mixed-lymphocyte reaction (MLR) assay
CD4+ T cells from splenocyte suspensions from BALB/c
mice were isolated using a CD4+ T cell isolation kit II, and
the purity was greater than 95 %. On culture day 6,
BMDCs were incubated with or without HemoHIM and
LPS for 24 h. Mature BMDCs were harvested, treated with
50 μg/ml of MMC for 25 min, and then washed. OVA257-
264-specific CD8
+ T cells were obtained from splenocyte
suspensions from C57BL/6 OT-1 T-cell receptor (TCR)
transgenic mice. CD4+ T cells were co-cultured with
BMDCs, and CD4+ T cell proliferation was determined
using a 5-bromo-2′-deoxy-uridine Labeling and Detection
Kit III. In addition, cytokine secretion by CD4+ T cells was
determined using an ELISA. The results are expressed as
the mean of triplicate experiments. OVA257-264-specific
CD8+ T cells were washed with PBS, labeled with 1 μM
CFSE in PBS, co-cultured with BMDCs in 96-well U-
bottom plates for 2 days, harvested, and washed with PBS.
Proliferation was then evaluated via flow cytometry.
OVA257-264-specific CD8
+ T cells were co-cultured with
BMDCs for 1 day, and cytokine secretion and intracellular
cytokine concentrations were determined by ELISA and
flow cytometry.
Cytokine assay
Culture supernatants were analyzed by enzyme-linked
immunosorbent assay (ELISA). The levels of various cy-
tokines secreted by BMDCs, allogeneic CD4+ T cells,
OVA-specific Th1 cells, and CD8+ T cells were measured
by ELISA.
Intracellular staining
CD8+ T cells were stained with biotin-anti-CD8 in the
presence of anti-FcR (2.4G2), fixed with 4 % paraformal-
dehyde in PBS, permeabilized with 0.1 % saponin, and
stained with FITC-anti-IFN-γ and PE-anti-CD8. CD8+ T
cells were then gated and analyzed using a FACScanto II
(BD Biosciences).
Statistical analysis
The differences between groups are presented as the mean
± S.D. of three replicate experiments. The significance of
differences was determined using the Student′s t-test. Prob-
ability values of < 0.05 were considered significant (P values
are indicated as follows: * < 0.05, ** < 0.01, *** < 0.001, or + <
0.05, ++ < 0.01, +++ < 0.001).
Results
HemoHIM is not cytotoxic to BMDCs
We investigated whether HemoHIM at different concen-
trations induces apoptosis in BMDCs. As shown in Fig. 1,
HemoHIM did not induce BMDC apoptosis at any of
the examined concentrations.
HemoHIM induces the maturation of bone marrow-
derived DCs
Flow cytometry was used to assess the expression of
BMDC maturation markers, including CD40, CD80,
CD86, and MHC I and II. In this experiment, BMDCs
treated with LPS were used as a positive control. As
shown in Fig. 2a, untreated BMDCs expressed CD40
(6.7 %), CD80 (58.1 %), CD86 (57.9 %), MHC I (31.2 %),
and MHC II (64.8 %), where the listed percentages are
indicate the percentage of cells expressing these markers.
Fig. 1 HemoHIM was not cytotoxic to BMDCs. BMDCs were treated with the indicated concentrations (1 μg/ml, 10 μg/ml and 100 μg/ml) of
HemoHIM for 24 h, stained with Annexin V-FITC and PI, and analyzed by flow cytometry. The results are representative of three experiments
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Fig. 2 HemoHIM induced the phenotypic maturation of BMDCs. a BMDCs were treated with the indicated concentrations of LPS or HemoHIM for
24 h. Flow cytometry was used to assess the expressions of co-stimulatory molecules by CD11c+-gated BMDCs. The mean fluorescence intensities
(M.F.I) and the percentages of positive cells are shown in each panel. b IL-1β, IL-6, IL-12p70, and TNF-α levels in HemoHIM-treated BMDCs were
analyzed by ELISA. The results are representative of three experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. untreated BMDCs. c Antigen
uptake activities at 37 °C were assessed based on dextran-FITC uptake using flow cytometry. The percentages of dextran-FITC+ CD11c+ cells are
indicated. The results are representative of three experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. untreated BMDCs. Not detection (N.D)
showed less than 10 pg/ml of cytokine secretion in this experiment
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Compared to untreated BMDCs, BMDCs treated with
LPS expressed higher levels of surface maturation
markers: CD40 (75.1 %), CD80 (87.9 %), CD86 (80.3 %),
MHC I (74.7 %), and MHC II (90.0 %). In addition,
BMDCs treated with HemoHIM at concentrations of
1 μg/ml, 10 μg/ml and 100 μg/ml exhibited increased
expression of surface markers. In particular, BMDCs
treated with HemoHIM (100 μg/ml) expressed signifi-
cantly higher levels of co-stimulatory molecules: CD40
(80.2 %), CD80 (73.1 %), CD86 (73.8 %), MHC I
(52.9 %), and MHC II (85.2 %). These surface markers
of BMDC maturation activate T cell responses via cell-
to-cell interactions. However, this phenomenon re-
quires interactions between surface markers and cyto-
kines [1–10]. During maturation, BMDCs expressed
higher levels of various co-stimulatory molecules and
cytokines [1–10]. Cytokines, such as, IL-1β, IL-6, IL-
12p70, and TNF-α, are important markers of BMDC
maturation [1–10]. In particular, IL-12p70 is an import-
ant marker of DC maturation and stimulates Th1 cells
Fig. 3 HemoHIM-treated BMDCs induced the activations of allogeneic CD4+ T cells derived from BALB/c mice. a CD4+ T cells were co-cultured
for 48 h with C57BL/6-derived BMDCs that were treated with LPS (1 μg/ml) or HemoHIM (100 μg/ml). The proliferation of allogeneic CD4+ T cells
was assessed using a Bromo-kit. b Culture supernatants were harvested after 48 h, and cytokine levels were measured by ELISA. The results are
representative of three experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. CD4+ T cells co-cultured with untreated BMDCs. Not detection
(N.D) showed less than 10 pg/ml of cytokine secretion in this experiment
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[1–10]. In this experiment, BMDCs treated with LPS
were used as a positive control. The secretion of IL-
12p70 by BMDCs treated with a high concentration of
HemoHIM (100 μg/ml) was higher than that of un-
treated BMDCs (Fig. 2b). The secretion of IL-1β, IL-6,
and TNF-α by BMDCs exhibited similar patterns. Im-
mature DCs have high antigen-uptake abilities, but
after maturation, the cells lose this ability and mature
into APCs [1–10]. Therefore, we examined whether
mature DCs exhibited reduced antigen-uptake activity.
BMDCs cultured in the presence or absence of Hemo-
HIM or LPS were incubated with FITC-dextran for
24 h, and FITC-dextran-positive cells were then ana-
lyzed by flow cytometry. We found that the antigen up-
take activity of HemoHIM-treated BMDCs was
significantly lower than that of untreated BMDCs
[(Fig. 2c) untreated: 30.3 % ±0.6, HemoHIM: 17.4 %
±1.4)]. Parallel experiments were performed at 4 °C
to examine the non-specific uptake of FITC-dextran
by BMDCs. At 4 °C, FITC-dextran was internalized
by fewer than 5 % of DCs. Furthermore, HemoHIM-
treated mature DCs exhibited a lower antigen uptake
capacity for FITC-dextran than immature DCs,
indicating that HemoHIM was more functionally ac-
tive in mature DCs. These finding suggest that
HemoHIM enhances the phenotypic and functional
maturation of BMDCs.
HemoHIM-treated bone marrow-derived DCs enhance
allogeneic CD4+ T cell proliferation
To examine the ability of HemoHIM-treated BMDCs to
increase CD4+ and CD8+ T cell responses, we performed
an allogeneic MLR assay using BALB/c CD4+ T cells.
CD4+ T cells were co-cultured with untreated BMDCs,
LPS-treated BMDCs, or HemoHIM-treated BMDCs.
After co-culture for 2 days, CD4+ T cells co-cultured
with HemoHIM-treated BMDCs were found to induce
more CD4+ T cell proliferation than CD4+ T cells co-
cultured with untreated BMDCs (Fig. 3a). To determine
whether HemoHIM-treated BMDCs modulate cytokine
secretion during allogeneic T cell responses, we mea-
sured IL-2, IFN-γ, and IL-4 levels in supernatants after
co-culture for 2 days. HemoHIM-treated BMDCs co-
cultured with CD4+ T cells secreted higher levels of
IFN-γ, IL-4, and IL-2 than untreated BMDCs (Fig. 3b).
In addition, the proliferation and cytokine secretion of
Fig. 4 HemoHIM-treated BMDCs induced the activation of antigen-specific Th1 cells. a OVA-specific Th1 cells were co-cultured for 48 h with
C57BL/6-derived BMDCs that were treated with LPS (1 μg/ml) or HemoHIM (100 μg/ml). The proliferation of OVA-specific Th1 cells was then assessed using
a Bromo-kit. b Culture supernatants were harvested after 24 h, and cytokine levels were measured by ELISA. The results are representative of three
experiments. *, p< 0.05, **, p< 0.01, and ***, p< 0.001 vs. OVA-specific T cells co-cultured with untreated BMDCs. +, p< 0.05, ++, p< 0.01, and +++, p< 0.001
vs. OVA-specific T cells co-cultured with OVA-pulsed BMDCs. Not detection (N.D) showed less than 10 pg/ml of cytokine secretion in this experiment
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CD4+ T cells increased in accordance with the T cell to
DC ratio, and IFN-γ production increased more than IL-4
production (Fig. 3b). These results suggest that the activa-
tion and maturation of BMDCs by HemoHIM activates T
cells and enhances Th1 responses.
HemoHIM-treated bone marrow-derived DCs enhance
antigen-specific CD4+ Th1 cell activation
Next, we investigated whether HemoHIM treated BMDCs
enhance antigen-specific CD4+ Th1 cell responses using
OVA-specific Th1 cells. To measure the proliferation and
cytokine secretion of OVA-specific Th1 cells, we co-
cultured OVA-specific Th1 cells with or without treated
BMDCs (LPS or HemoHIM). OVA-specific Th1 cells co-
cultured with HemoHIM-treated BMDCs proliferated
more than cells co-cultured with untreated BMDCs
(Fig. 4a). Furthermore, OVA-specific Th1 cells co-cultured
with HemoHIM-treated BMDCs secreted significantly
more IFN-γ than cells co-cultured with untreated BMDCs
(Fig. 4b), indicating that HemoHIM enhances antigen-
specific Th1 cell responses induced by activated DCs.
HemoHIM-treated bone marrow-derived DCs enhance OT-
1 CD8+ T cell activation
The presentation of captured antigens to cytotoxic CD8+ T
cells is important for the induction of anti-tumor immunity.
To examine the ability of HemoHIM-treated BMDCs to in-
crease antigen-presentation to CD8+ T cells, we used OT-1
mice. CFSE-labeled CD8+ T cells were co-cultured with un-
treated BMDCs pulsed with OVA257-264 or treated BMDCs
(LPS or HemoHIM) pulsed with OVA257-264. CD8
+ T cells
co-cultured with HemoHIM-treated BMDCs proliferated
more than CD8+ T cells co-cultured with untreated
BMDCs (Fig. 5). Furthermore, CD8+ T cells co-cultured
with HemoHIM-treated BMDCs produced significantly
more IFN-γ than those co-cultured with untreated BMDCs,
presumably due to the secretion of intracellular cytokines
(Fig. 6a) and the production (Fig. 6b) of cytokines. These
results supported the notion that HemoHIM enhances
CD8+ T cell responses by activating DCs.
HemoHIM induces TLR4-mediated BMDC maturation
Associations between activated DCs and TLRs are crit-
ical for the tailoring of immune responses. We investi-
gated whether TLRs on BMDCs recognized HemoHIM
using TLR2-/- and TLR4-/- mice. To confirm that TLRs
on BMDCs interact with HemoHIM, wild-type, TLR2-/-,
or TLR4-/- BMDCs were stimulated with HemoHIM for
24 h. Pam3 (a TLR2 agonist) and LPS (a TLR4 agonist)
were used as positive controls. After stimulation for
24 h, we measured the expressions of the BMDCs mat-
uration markers CD40, CD80, CD86, and MHC II and
Fig. 5 HemoHIM-treated BMDCs induced the activation of CD8+ T cells derived from C57BL/6 OT-1 mice. CD8+ T cells were stained with CFSE
and co-cultured for 48 h with C57BL/6-derived BMDCs that were treated with LPS (1 μg/ml) or HemoHIM (100 μg/ml). The proliferation of CD8+ T
cells was assessed by flow cytometry. The results are representative of three experiments. *, p< 0.05, **, p< 0.01, and ***, p< 0.001 vs. OVA257-264-specific T
cells co-cultured with untreated BMDCs. +, p< 0.05, ++, p< 0.01, and +++, p< 0.001 vs. OVA257-264-specific T cells co-cultured with OVA257-264-pulsed BMDCs
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of various cytokines (i.e., IL-1β, IL-6, and TNF-α). As
shown in Fig. 7a, untreated BMDCs from wild-type,
TLR2-/-, and TLR4-/- mice expressed similar levels of these
markers and cytokines. However, HemoHIM-treated
BMDCs from wild-type and TLR2-/- mice exhibited higher
expression of the investigated surface maturation markers
than untreated wild-type or TLR2-/- BMDCs [wild-type:
CD40 (24.4 %), CD80 (75.5 %), CD86 (76.1 %), and MHC
II (75.7 %); and TLR2-/- : CD40 (28.5 %), CD80 (78.3 %),
CD86 (74.6 %), and MHC II (67.6 %)]. In contrast, these
effects were diminished in BMDCs from TLR4-/-mice, in-
dicating that HemoHIM is an agonist of TLR4 in BMDCs
[TLR4-/- : CD40 (14.4 %) and CD80 (67.9 %)]. In contrast,
the expression levels of CD80 and CD86 were significantly
more reduced by HemoHIM in BMDCs from TLR4-/-
mice than in BMDCs from wild-type or TLR2-/- mice
[wild-type: CD80 (75.5 %) and CD86 (76.1 %); TLR2-/- :
CD80 (78.3 %) and CD86 (74.6 %); and TLR4-/- : CD80
(67.9 %) and CD86 (67.8 %)]. In addition, cytokine
production exhibited a pattern similar to that observed
for surface molecules (Fig. 7b). These results demon-
strate that HemoHIM induces TLR4-mediated BMDC
maturation.
HemoHIM enhances DCs maturation in vivo
Through the results of the previous, we demonstrated
that HemoHIM enhances the phenotypic and functional
maturation of BMDCs and matured BMDCs by Hemo-
HIM enhances antigen-specific T cell responses through
in vitro. Likewise, we investigated whether HemoHIM
enhanced function of s-DCs in vivo by oral administra-
tion HemoHIM. Mice were orally administered for
4 weeks. After 4 weeks, we isolated s-DCs in the spleen
of mice each groups. After isolation, s-DCs were stimu-
lated with LPS (100 ng/ml) for 24 h in order to matur-
ation degree of s-DCs by LPS. After 24 h, we measured
the expression of DC maturation markers such as CD40,
CD80, CD86, MHC I, and MHC II and secretion cyto-
kine IL-12p70. In the two groups, the results that s-DCs
in the group with oral administration HemoHIM higher
increased degree of maturation by LPS than s-DCs in
the group with oral administration D.W through CD40
and CD80 among maturation markers. Also IL-12p70
secretion by s-DCs treated LPS was increased by admin-
istration HemoHIM group than by administration D.W
group (Fig. 8a, b). Next we experimented that matured
s-DCs of group with oral administered HemoHIM
Fig. 6 HemoHIM-treated BMDCs induced the activation of allogeneic CD8+ T cells derived from C57BL/6 OT-1 mice. CD8+ T cells were co-cultured for
24 h with C57BL/6-derived BMDCs that were treated with LPS (1 μg/ml) or HemoHIM (100 μg/ml). a Flow cytometry of intracellular IFN-γ staining in
CD8+ T cells. b Culture supernatants were harvested after 24 h, and cytokine levels were measured by ELISA. The results are representative of three
experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. OVA257-264-specific T cells co-cultured with untreated BMDCs.
+, p < 0.05, ++, p < 0.01, and +++,
p < 0.001 vs. OVA257-264-specific T cells co-cultured with OVA257-264-pulsed BMDCs. Not detection (N.D) showed less than 10 pg/ml of cytokine secretion
in this experiment
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enhance antigen-specific T cell response with OVA-
specific T cells than group with oral administered D.W.
Proliferation and cytokine secretion of OVA specific T
cell co-cultured OVA-pulsed s-DCs significantly increase
by administration HemoHIM group than by administra-
tion D.W group. This result (Fig. 9) that HemoHIM en-
hanced functional maturation of s-DCs by in vivo.
Discussion
Diseases are caused by the failure to induce appropriate
immune responses to invading pathogens or tumor cells.
Tumors are well-known sources of biological substances
and release immunosuppressive factors to evade the host
immune surveillance system [2, 46–48]. During neoplas-
tic disease development, the body’s natural defenses are
typically attenuated [49–51]. In particular, DCs that have
infiltrated tumor tissues are known to exhibit reduced
expressions of surface molecules and to produce fewer
cytokines; this finding implies that tumor-derived factors
impede DC maturation [49–51]. Furthermore, these ef-
fects appear to be maturation-dependent and to act on
DC precursors rather than on mature DCs [2]. Recent
studies indicate that DCs are the most potent immune
cell vaccine candidate and that mature DCs are likely
the best cell type for clinical use [2]. Immature DCs cap-
ture antigens generated by pathogens and tumors and
then enter a maturation cascade. The resulting mature
DCs exhibit elevated expression of co-stimulatory mole-
cules and secrete more cytokines to promote immune
synapse formation, antigen processing, antigen presenta-
tion to T cells, and T cell activation [10]. Therefore, DCs
could potentially be used in vaccines for tumor-
immunotherapy and to treat other diseases [52, 53]. In this
study, we focused on the enhancement of DC activity. As
Fig. 7 HemoHIM bound TLR4 but not TLR2 and induced BMDC activation. a Histograms of CD40, CD80, CD86, and MHC II expression by
HemoHIM treated (100 μg/ml) CD11c-gated DCs derived from wild-type, TLR2-/-, or TLR4-/- mice. DCs derived from wild-type, TLR2-/- and TLR4-/- mice
were treated with HemoHIM for 24 h. The percentages of positive cells are shown in each panel. b IL-1β, IL-6, and TNF-α production by HemoHIM-, LPS-,
or Pam3-treated DCs derived from wild-type, TLR2-/-, or TLR4-/- mice were determined by ELISA. The results are representative of three experiments. *,
p< 0.05, **, p< 0.01, and ***, p< 0.001 vs. untreated BMDCs. +, p< 0.05, ++, p< 0.01, and +++, p< 0.001 vs. HemoHIM-treated BMDCs from wild-type and
TLR2-/- mice
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Fig. 8 HemoHIM induced the phenotypic maturation and cytokine secretion of DCs in vivo. S-DCs was treated with the indicated concentrations
of LPS for 24 h. a Flow cytometry was used to analyze the expressions of co-stimulatory molecules on CD11c+-gated s-DCs. Mean fluorescence
intensities (M.F.I) of positive cells are shown for each panel. b IL-12p70 levels in HemoHIM-oral administration mice s-DCs were analyzed by ELISA.
Results are representative of three experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. untreated BMDCs. +, p < 0.05, ++, p < 0.01, and +++,
p < 0.001 vs. LPS treated DCs of control group
Fig. 9 S-DCs of HemoHIM-oral administration mice induced the activation of antigen-specific T cells. OVA-specific T cells co-cultured for 48 h with
s-DCs of each group pulsed with OVA (100 μg/ml). a The proliferation of OVA-specific T cells was assessed by flow cytometry. b Culture supernatants
were harvested after 24 h, and IFN-γ levels were measured by ELISA. Results are representative of three experiments. +, p < 0.05, ++, p < 0.01,
and +++, p < 0.001 vs. OVA-specific T cells co-cultured with untreated s-DC. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 vs. OVA-specific T cells
co-cultured with OVA-pulsed DCs of control group. Not detection (N.D) showed less than 10 pg/ml of cytokine secretion in this experiment
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mentioned above, HemoHIM has several biological activ-
ities and is non-cytotoxic, but it remained unknown
whether HemoHIM modulates T cell responses in a DC-
mediated manner. The present study demonstrates that
HemoHIM interacts with BMDCs and induces DC matur-
ation and that these events result in up-regulated expres-
sion of co-stimulatory molecules and the loss of the ability
to take up antigens. Furthermore, HemoHIM-treated
BMDCs were found to secrete considerably more cyto-
kines (i.e., IL-1β, IL-6, IL-12p70, and TNF-α) than
untreated cells. Of the cytokines secreted by DCs, IL-
12p70 is most important in the context of DC maturation
because this ctokine induces the differentiation of naïve
CD4+ T cells into Th1 cells [9, 10]. In the present study,
HemoHIM was found to induce the phenotypic and func-
tional maturation of DCs, indicating that this treatment
has immunoadjuvant potential, as suggested previously
[1–10]. After maturation, DCs interact with T cells using
co-stimulatory molecules and cytokines. The present
study demonstrates that DCs that mature in response to
HemoHIM induce greater proliferation and cytokine se-
cretion by allogeneic CD4+ T cells and OVA-specific Th1
cells than their untreated counterparts. In particular, IFN-
γ secretion was more enhanced than IL-4 secretion. It is
also possible HemoHIM induces Th1 response because
IL-12p70 is associated with Th1 activation. In addition, in
the present study, HemoHIM-treated BMDCs enhanced
CD8+ T cell responses in OT-1 mice. These results dem-
onstrated that HemoHIM-treated BMDCs induce T cell
activation and suggest that HemoHIM-treated BMDCs
may more effectively induce T cell responses against
antigens.
TLR ligands are promising candidate immune stimula-
tory adjuvants for tumor-therapy [12] and have been re-
ported to be expressed on APCs, including immune cells,
and to be required for immune responses [54–56]. More-
over, TLR4 has been reported to induce Th1 responses in
studies of immune adjuvants for tumor-therapy [54–56].
In the present study, co-stimulatory molecule expression
and the amount of cytokines secreted by HemoHIM-
treated BMDCs from TLR4-/- mice were decreased, while
cytokine secretion by BMDCs from wild-type and
HemoHIM-treated TLR2-/- mice were increased. Previous
studies of a variety of immunoadjuvant plant extracts that
function via DC-mediated immune responses have fo-
cused on TLR4 agonists [10, 57, 58]. However, HemoHIM
is an herbal mixture, and perhaps only one of its compo-
nents is recognized by TLR4.
The present study demonstrates that HemoHIM in-
duces the phenotypic and functional maturation of DCs,
which initiate T cell responses, including specific-CD8+
T cell responses and specific-CD4 Th1 responses, in a
TLR-4 mediated manner. Also, we proved that Hemo-
HIM enhances functional maturation of s-DCs by in
vivo. HemoHIM in combination with cisplatin was pre-
viously reported to have anti-cancer effects in vitro and
in vivo [31], and the present study suggests that these ef-
fects are due to the enhancement of T cell responses
when DCs are treated with HemoHIM. Accordingly, our
findings indicate that HemoHIM is a potential tumor-
therapy that enhances DC-based T cell responses.
Conclusions
In summary, our study demonstrated that HemoHIM
induces TLR4-mediated BMDCs maturation. Further-
more, we showed the antigen-presenting ability that
HemoHIM-treated mature BMDCs increase CD4+ and
CD8+ T cell responses by in vitro. Therefore, HemoHIM
has the potential dendritic cell-based immunoadjuvant.
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